{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:48:56Z","timestamp":1788371336478,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-025-03479-y","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T11:34:24Z","timestamp":1770032064000},"page":"1327-1340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed\/Refractory Multiple Myeloma with 2\u20134 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03548207","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04181827","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03651128","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nieves","family":"Lopez-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noffar","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Diels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy","family":"van Sanden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seina","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"3479_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"3479_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97:1086\u2013107.","journal-title":"Am J Hematol"},{"key":"3479_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/jnci\/djae321","volume":"117","author":"A Mafra","year":"2025","unstructured":"Mafra A, Laversanne M, Marcos-Gragera R, et al. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. J Natl Cancer Inst. 2025;117:907\u201314.","journal-title":"J Natl Cancer Inst"},{"key":"3479_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252\u201364.","journal-title":"Br J Haematol"},{"issue":"1","key":"3479_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/cancers15010155","volume":"15","author":"F de Arriba De la Fuente","year":"2022","unstructured":"de Arriba De la Fuente F, Montes Gaisan C, de la Rubia CJ. How to manage patients with lenalidomide-refractory multiple myeloma. Cancers (Basel). 2022;15(1):155.","journal-title":"Cancers (Basel)"},{"key":"3479_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41408-019-0200-1","volume":"9","author":"P Moreau","year":"2019","unstructured":"Moreau P, Zamagni E, Mateos MV. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer J. 2019;9:38.","journal-title":"Blood Cancer J"},{"key":"3479_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115157","volume":"215","author":"K Yong","year":"2025","unstructured":"Yong K, Einsele H, Schecter JM, et al. Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: analysis of individual patient-level data from daratumumab clinical trials. Eur J Cancer. 2025;215:115157.","journal-title":"Eur J Cancer"},{"key":"3479_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.01.009","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, He J, Schecter JM, et al. Real-world treatment patterns and outcomes in patients with lenalidomide-refractory multiple myeloma with 1 to 3 prior lines: SEER-Medicare database. Clin Lymphoma Myeloma Leuk. 2025. https:\/\/doi.org\/10.1016\/j.clml.2025.01.009.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3479_CR9","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/s41375-024-02404-6","volume":"38","author":"MV Mateos","year":"2024","unstructured":"Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma - 2-year follow-up (final analysis). Leukemia. 2024;38:2554\u201360.","journal-title":"Leukemia"},{"key":"3479_CR10","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"3479_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"key":"3479_CR12","unstructured":"CARVYKTI\u00ae (ciltacabtagene autoleucel). Prescribing information. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf. Accessed 26 November 2025."},{"key":"3479_CR13","unstructured":"European Medicines Agency. CARVYKTI (ciltacabtagene autoleucel) Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carvykti-epar-product-information_en.pdf. Accessed 26 November 2025."},{"key":"3479_CR14","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"3479_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"3479_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"3479_CR17","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, et al. Long-term (>\/=5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43:2766\u201371.","journal-title":"J Clin Oncol"},{"key":"3479_CR18","doi-asserted-by":"crossref","unstructured":"Mateos M-V, San-Miguel J, Dhakal B, et al. Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: Phase 3 CARTITUDE-4 study update. Presented at the 21st International Myeloma Society (IMS) Annual Meeting; September 25\u201328, 2024; Rio de Janeiro, Brazil.","DOI":"10.1016\/S2152-2650(24)02346-2"},{"key":"3479_CR19","unstructured":"ABECMA\u00ae (idecabtagene vicleucel), suspension for intravenous infusion. Prescribinginformation. https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf. Accessed 26 November 2025."},{"key":"3479_CR20","unstructured":"European Medicines Agency. Abecma (idecabtagene vicleucel) Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/abecma-epar-product-information_en.pdf. Accessed 26 November 2025."},{"key":"3479_CR21","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"3479_CR22","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","volume":"144","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Arnulf B, Patel K, et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024;144:2389\u2013401.","journal-title":"Blood"},{"key":"3479_CR23","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1080\/03007995.2024.2391112","volume":"40","author":"N Bar","year":"2024","unstructured":"Bar N, Diels J, van Sanden S, et al. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison. Curr Med Res Opin. 2024;40:1597\u2013603.","journal-title":"Curr Med Res Opin"},{"key":"3479_CR24","unstructured":"Phillippo DM, Ades T, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. Report by the Decision Support Unit. 2016."},{"key":"3479_CR25","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137.","journal-title":"Value Health"},{"key":"3479_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"3479_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167:268\u201374.","journal-title":"Ann Intern Med"},{"key":"3479_CR28","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.annonc.2023.06.002","volume":"34","author":"B Kiesewetter","year":"2023","unstructured":"Kiesewetter B, Dafni U, de Vries EGE, et al. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0. Ann Oncol. 2023;34:734\u201371.","journal-title":"Ann Oncol"},{"key":"3479_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1017\/S0266462319000333","volume":"35","author":"DM Phillippo","year":"2019","unstructured":"Phillippo DM, Dias S, Elsada A, Ades AE, Welton NJ. Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence technology appraisals. Int J Technol Assess Health Care. 2019;35:221\u20138.","journal-title":"Int J Technol Assess Health Care"},{"issue":"885","key":"3479_CR30","first-page":"e1","volume":"30","author":"MD Ray","year":"2024","unstructured":"Ray MD, Kanters S, Beygi S, et al. Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed\/refractory follicular lymphoma. Transplant Cell Ther. 2024;30(885):e1\u201311.","journal-title":"Transplant Cell Ther"},{"key":"3479_CR31","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1007\/s12325-024-02822-z","volume":"41","author":"G Salles","year":"2024","unstructured":"Salles G, Chen JMH, Zhang I, et al. Matching-adjusted indirect comparison of brexucabtagene autoleucel (ZUMA-2) and pirtobrutinib (BRUIN) in patients with relapsed\/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor. Adv Ther. 2024;41:1938\u201352.","journal-title":"Adv Ther"},{"key":"3479_CR32","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1080\/10428194.2022.2113526","volume":"63","author":"OO Oluwole","year":"2022","unstructured":"Oluwole OO, Chen JMH, Chan K, et al. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leuk Lymphoma. 2022;63:3052\u201362.","journal-title":"Leuk Lymphoma"},{"key":"3479_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40164-022-00268-z","volume":"11","author":"G Cartron","year":"2022","unstructured":"Cartron G, Fox CP, Liu FF, et al. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel. Exp Hematol Oncol. 2022;11:17.","journal-title":"Exp Hematol Oncol"},{"key":"3479_CR34","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1007\/s12325-021-01756-0","volume":"38","author":"G Salles","year":"2021","unstructured":"Salles G, Spin P, Liu FF, Garcia J, Kim Y, Hasskarl J. Indirect treatment comparison of liso-cel vs. salvage chemotherapy in diffuse large B-cell lymphoma: TRANSCEND vs. SCHOLAR-1. Adv Ther. 2021;38:3266\u201380.","journal-title":"Adv Ther"},{"key":"3479_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40164-025-00610-1","volume":"14","author":"LJ Nastoupil","year":"2025","unstructured":"Nastoupil LJ, Bonner A, Wang P, et al. Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma. Exp Hematol Oncol. 2025;14:30.","journal-title":"Exp Hematol Oncol"},{"key":"3479_CR36","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","volume":"37","author":"T Martin","year":"2021","unstructured":"Martin T, Usmani SZ, Schecter JM, et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021;37:1779\u201388.","journal-title":"Curr Med Res Opin"},{"key":"3479_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/03007995.2022.2139052","volume":"39","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Schecter JM, et al. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2023;39:81\u20139.","journal-title":"Curr Med Res Opin"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03479-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03479-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03479-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:29:46Z","timestamp":1773822586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03479-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3479"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03479-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nieves Lopez-Mu\u00f1oz: nothing to disclose. Noffar Bar: nothing to disclose. Tadao Ishida: research funding from Alexion Pharma, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Pfizer, Prothena, Sanofi, and Takeda; honoraria from Bristol-Myers Squibb, CSL Behring, Johnson & Johnson, Ono, Pfizer, Sanofi, and Takeda. Jeremy Er: nothing to disclose. Simon J Harrison: advisory board for Celgene Corporation, F. Hoffmann-La Roche AG, Genentech USA, Inc., HaemaLogiX Pty Ltd, Johnson & Johnson, and Novartis; research funding from Johnson & Johnson and HaemaLogiX Pty Ltd. Joris Diels, Suzy van Sanden, Jo\u00e3o Mendes, Seina Lee, Teresa Hernando, and Nikoletta Lendvai: employees of Johnson & Johnson and may own stock in Johnson & Johnson. Nitin Patel: an employee of Legend Biotech USA Inc and has stock and other ownership interests in Legend Biotech.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The CARTITUDE-1, CARTITUDE-4, and KarMMa-3 trials were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation guidelines for Good Clinical Practice. The protocols were approved by the ethics committee or the institutional review board (Supplementary Tables S1 and S2). All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}